Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 204, Issue 4, Pages 626-635Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jir351
Keywords
-
Categories
Funding
- Merck
- Fujisawa
- Enzon
- Pfizer
- Schering-Plough
- M. D. Anderson Cancer Center Faculty
- National Institutes of Health [CA016672, AI069397]
Ask authors/readers for more resources
The identification of FKS1 mutations in Candida albicans associated with echinocandin resistance has raised concerns over the spread of drug-resistant strains. We studied the impact of fks1 mutations on C. albicans virulence and fitness. Compared with wild-type strains for FKS1, echinocandin-resistant C. albicans strains with homozygous fks1 hot-spot mutations had reduced maximum catalytic capacity of their glucan synthase complexes and thicker cell walls attributable to increased cell wall chitin content. The fks1 mutants with the highest chitin contents had reduced growth rates and impaired filamentation capacities. Fks1 mutants were hypovirulent in fly and mouse models of candidiasis, and this phenotype correlated with the cell wall chitin content. In addition, we observed reduced fitness of echinocandin-resistant C. albicans in competitive mixed infection models. We conclude that fks1 mutations that confer echinocandin resistance come at fitness and virulence costs, which may limit their epidemiological and clinical impact.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available